TYME Leadership

RICHIE CUNNINGHAM, Chief Executive Officer

Mr. Cunningham is our Chief Executive Officer as of November 2020 and brings more than 20 years of successful leadership experience spanning from pre-IND drug discovery through the commercialization and launch of over a dozen therapies in oncology, rare disease, infectious disease, respiratory, neurology, cardiovascular and metabolic diseases. Richie brings to TYME an in-depth understanding of maximizing therapeutic lifecycles, enhancing efficiencies and outcomes in biotech business models, and most importantly a commitment to a value driven culture.

Mr. Cunningham also brings significant experience in mergers & acquisitions, business development, strategy development, therapeutic launches, contracting, managed care, and sales & marketing. Most recently, Richie served as CEO at Icagen, leading the company through two transformational acquisitions, acquiring assets and talent out of Pfizer and Sanofi. While CEO at Icagen, he successfully negotiated and signed multiple licensing deals with Roche, Sanofi and the Cystic Fibrosis Foundation.

Prior to joining Icagen, Mr. Cunningham was an executive with one of the world’s largest pharmaceutical companies, Boehringer Ingelheim, where he held a variety of key strategic and operational roles, including the launch of Boehringer’s first entrance into the oncology market with Gilotrif® (afatinib), an oral tyrosine kinase inhibitor, as a treatment for patients with non-small cell lung cancer.

Steven Hoffman, Chief Science Officer

Steve Hoffman co-founded TYME and is our Chairman of the board and Chief Science Officer. Steve served as our Chief Executive Officer from March 2015 to November 2020. Mr. Hoffman has over 30 years of experience in biochemistry and physics, and has been the lead author on over 40 patents. For the last decade, he has focused on biopharmaceuticals for oncology, metabolic syndrome, and central nervous system disorders. Prior to working in biotech, he was involved in projects related to chemistry, aerospace and laser optics. In addition to leading the scientific development for his own companies, he has worked with multiple Fortune 500 healthcare companies, academic institutions, and the US government.

Jan M. Van Tornout,, MD, MSc, Acting Chief Medical Officer

Dr. Van Tornout brings over 25 years of medical experience in academia and industry, including over 15 years of global drug development in pharmaceutical and biotech settings and encompassing preclinical, IND, FIH, phase II-IV, (s)NDA, BLA, safety, medical affairs, clinical operations and regulatory experience. He has led clinical management and oncology teams at Natera, INOVIO Pharmaceuticals, Astellas Pharma, Bristol Myers Squibb and Amgen. Dr. Van Tornout has also served as a medical strategy consultant for various biotech companies including Cyclacel Pharmaceuticals, GlaxoSmithKline, Puma Biotechnology, Maverick Therapeutics, ERT, Huya Bioscience, and Gradalis. Dr. Van Tornout previously held academic appointments at the University of Southern California (USC) with clinical appointments at Children’s Hospital Los Angeles as attending pediatric hematologist-oncologist. Dr. Van Tornout received his MD from the Katholieke Universiteit Leuven (KUL), Leuven, Belgium, an MS in classical philosophy from KUL, and a BS from the Faculté Notre-Dame de la Paix, Namur, Belgium. He obtained his certification as a paediatrician from the Gasthuisberg University Hospitals, KUL, and subsequently completed his training as a pediatric hematologist-oncologist at Children’s Hospital Los Angeles, USC. He earned an MSc. in applied biometry from USC and completed a post-doctoral fellowship in molecular epidemiology at USC. Subsequently his National Institutes of Health-sponsored laboratory focused on genetic epidemiology of childhood cancer (EWS) and the application of neural networks to the analysis of large pediatric cancer datasets.

FRANK L. PORFIDO, Chief Financial Officer

Mr. Porfido is a well-established biotech and pharmaceutical industry executive with over 25 years of strategic financial leadership expertise. Throughout his career, Mr. Porfido has demonstrated a track record of building and leading cross-functional teams. Collectively, he spent over 15 years at Novartis in various leadership roles, including serving as the Global Head of Finance for their Oncology Business Unit and Head of Global Finance for their Oncology Translational Medicines (OTM) Unit. He was responsible for developing its global strategic plan for a $15 billion business unit and in his OTM position he was a member of a leadership team that managed the early-stage Oncology pipeline.

Most recently, Mr. Porfido served as the Vice President, Finance for UroGen Pharma, Inc., biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases. While there, he was responsible for day-to-day operations of Finance and played a key role in the launch of the company’s first commercial product. Prior to that, he served in various roles at Novartis including U.S. Country Chief Financial Officer for its Ophthalmology Business Unit, Infectious Disease Transplant Business Unit, and U.S. Oncology Business Unit.

Mr. Porfido is a Certified Public Accountant and received his BBA in Accounting-CPA Prep from Pace University, his MBA in Finance from Farleigh Dickinson University.

Jonathan Eckard,, PhD, Chief Business Officer

Jonathan Eckard has served as our Chief Scientific Affairs Officer since 2017 and assumed the role of Chief Business Officer in March 2019. Dr. Eckard has over 12 years of financial experience in equity research, bringing to us both important industry insights and comprehensive understanding of the healthcare equity capital markets. From 2016 to 2017, Dr. Eckard was Chief Business and Strategy Officer of SELLAS Life Science, a private oncology-focused biotechnology company. His previous finance roles include equity research analyst roles at Barclays Capital Markets, Citi Capital Markets, Leerink Swann, and HSBC Securities, where he primarily followed small to mid-sized biotechnology companies. Dr. Eckard received a Bachelor of Science degree in Biochemistry from Ohio University, a Master of Science degree in Toxicology and a PhD in Toxicology and Carcinogenesis from New York University School of Medicine.

James Biehl, Chief Legal Officer and Secretary

James Biehl has served as our Chief Legal Officer and Secretary since September 2018 and served on our board of directors from 2017 until September 2018. Mr. Biehl has over 30 years of experience as a corporate and securities lawyer representing big pharma, healthcare systems, healthcare consulting firms, and consumer products and medical device companies. His entire career was with the law firm of Drinker Biddle & Reath LLP where he joined the firm in 1989 and was a partner for over 20 years. Mr. Biehl received a Bachelor of Science degree in Industrial Management from Carnegie Mellon University and a Juris Doctor degree from Temple University Beasley School of Law.